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Abstract 
 Adulteration of Ginkgo products sold as unregistered supplements within the very large market of 
Ginkgo products (reputedly £650 million annually) through the post-extraction addition of cheaper 
(e.g. buckwheat derived) rutin is suspected to allow sub-standard products to appear satisfactory to 
third parties, e.g. secondary buyers along the value chain or any regulatory authorities. This study 
was therefore carried out to identify products that did not conform to their label specification and 
may have been actively adulterated to enable access to the global markets.  
500MHz Bruker NMR spectroscopy instrumentation combined with Topspin version 3.2 and a 
CAMAG HPTLC system (HPTLC Association for the analysis of Ginkgo biloba leaf) were used to 
generate NMR spectra (focusing on the 6-8ppm region for analysis) and chromatograms, 
respectively.  
Out of the 35 samples of Ginkgo biloba analysed, 33 were found to contain elevated levels of rutin 
and /or quercetin, or low levels of Ginkgo metabolites when compared with the reference samples. 
Samples with disproportional levels of rutin or quercetin compared with other gingko metabolites 
are likely to be adulterated, either by accident or intentionally, and those samples with low or non-
existent gingko metabolite content may have been produced using poor extraction techniques. Only 
two of the investigated samples were found to match with the High-Performance Thin-Layer 
Chromatography (HPTLC) fingerprint of the selected reference material. All others deviated 
significantly. One product contained a 5-hydroxytryptophan derivative, which is not a natural 
constituent of Ginkgo biloba.  
Overall, these examples either suggest a poor extraction technique or deliberate adulteration along 
the value chain. Investigating the ratio of different flavonoids e.g. quercetin and kaempferol using 
NMR spectroscopy and HPTLC will provide further evidence as to the degree and kind of adulteration 
of Gingko supplements. From a consumer perspective the equivalence in identity and overall quality 
of the products needs to be guaranteed for supplements too and not only for products produced 
according to a quality standard or pharmacopoeial monograph.  
 
 
 
 
 
Introduction 
Ginkgo biloba L. (Ginkgoaceae) is a popular phytomedicine with a high economic value. It is used 
principally for the treatment of problems associated with the peripheral circulation and to improve 
memory and cognitive function. It is a licensed drug in some European countries, e.g. Germany. In 
the UK, two products hold a Traditional Herbal Registration (THR) for the treatment of Raynaud’s 
disease although the majority of products on the UK market are sold as unlicensed food 
supplements (now often referred to as botanicals). 
According to ‘Industry Experts’, the global market for the sale of Ginkgo biloba supplements 
amounts to around £650 million annually (Daniells, 2013), typically ranging in price from 2.5 to 54 
pence per individual daily dose. However, there have been frequent reports of poor quality and 
adulteration ( Avula, et al., 2015; Edwards et al. 2015; Wohlmuth et al., 2014) .  
Manufacturers of extracts complying with pharmacopoeial standards have to perform extensive 
testing. Besides HPTLC, for identification, the European Pharmacopeia (Ph. Eur.) requires three HPLC 
assays (flavonoids, terpene lactones and ginkgolic acids) and the United States Pharmacopoeia (USP) 
requires four HPLC assays (content of free flavonol glycosides, content of terpene lactones, limit on 
rutin and quercetin, and limit of ginkgolic acids) (EP 2014, USP 2015). Supplement manufacturers 
may however choose not to claim compliance with a pharmacopeia and thus limit their analytical 
work to a minimum. Such simplified conventional testing is not always able to determine which 
products are of good quality, particularly as it has been reported that products are often ‘spiked’ 
with buckwheat-derived rutin in order to increase their total flavonoid content and to reduce the 
amount of authentic drug in the preparation (Ding et al., 2006). This has important implications for 
both the OTC market and the practitioner led market as middlemen involved in the early stages of 
the supply chain (cultivation and primary processing) may cross both markets.  
NMR spectroscopy is an effective tool for the quality control of medicinal plants or HMPs (Shyur and 
Yang, 2008). The advantages of NMR spectroscopy over other techniques for metabolomics 
applications include the relative ease of sample preparation, the potential to identify a broad range 
of compounds and provision of structural information for unknown entities (Zulak et al., 2008).  
NMR spectroscopy-Metabolomics coupled with HPTLC can offer a better picture of the total 
metabolite profiles that can be obtained from plants and plant extracts and so may be a useful 
addition to other analytical methods (Liu, 2015, López-Gutiérrez, 2016), in the investigation of fake, 
adulterated and poor quality products (Booker et al., 2015). 
 
Materials and methods 
Test samples 
35 Ginkgo products sold as food supplements were purposefully sampled from health food stores, 
supermarkets and pharmacies in the Central London area and from the internet. The internet search 
criteria used was ‘Ginkgo, Ginkgo biloba, Ginkgo Products and Buy Ginkgo products’.  The samples 
were marketed as either extracts of Ginkgo biloba formulated into tablets (22), hard capsules (11), 
or caplets (2). A detailed description of all investigated products is provided in the supplementary 
data.         
      
Solvents, reagents and chemicals 
Deuterated dimethyl sulfoxide D6 lot no. 14F-145 and tetramethylsilane (for NMR spectroscopy) 
(99.9%) were purchased from Cambridge Isotope Laboratories, Inc., Andover, MA, USA. Methanol 
was purchased from Carl Roth GmbH, Karlsruhe, Germany, ethylacetate (99.5%) and formic acid (98+ 
%) pure purchased from Acros, New Jersey, USA. Acetic acid (99.5%), toluene (99+%), acetone 
(pure), and dichloromethane (for HPTLC) were purchased from Sigma-Aldrich. Acetic anhydride 
(98.5%) was purchased from Merck. Polyethylene glycol, 2-aminoethyldiphenylborinate 
(Derivitisation reagents) were purchased from Aldrich chemistry.   
 
Standards 
Reference standard: A quantified and licensed Ginkgo extract tablet EGb 761 (Tebofortin® intense) 
and Ginkgo biloba extract tablets (LI 1370 extract) were purchased through a pharmacy. Ginkgo 
tablet (S1312) and Ginkgo biloba leaf (S1310) were obtained from the National Institute of Standards 
and Technology (NIST) U.S. Department of Commerce; Ginkgo biloba leaf samples (S11311, S15564) 
and powdered Ginkgo biloba leaf extracts (S10925 and S15571) were obtained from the American 
Herbal Pharmacopeia (AHP). Quercetin, chlorogenic acid, rutin, and ginkgo terpene lactones 
(mixture) and Ginkgo biloba standard supplied by The European Pharmacopoeia (EP CRS for peak 
identification) were obtained from Sigma-Aldrich.  
 
¹H-NMR spectroscopy 
Preparations of standard solutions and samples 
Approximately 50 mg of solid extracts were accurately weighed and transferred to a 1.5 ml 
Eppendorf reaction tube, 1 ml of deuterated DMSO containing 0.05% tetramethylsilane was added. 
The mixture was mixed on a rotary mixer for 60 s, sonicated for 10 minutes at room temperature 
and centrifuged for 10 minutes at room temperature (speed; 14,000 rpm). The reference standard 
solutions of rutin and Ginkgo biloba BRM were prepared at a concentration of 20 mg/ml in 
deuterated DMSO.  700 μl of supernatant was transferred to a 5 mm diameter NMR tube, and the 
samples were submitted on the same day for ¹H-NMR spectroscopy analysis.  
 
Apparatus and instrumentation 
The 1H-NMR spectra were acquired using 500 MHz NMR Bruker Avance spectrometer (Bruker 
BioSpin GmbH, Rheinstetten, Germany) equipped with a 5 mm cryoprobe head and operating at a 
proton frequency of 500.13 MHz. The acquisition parameters were: size of the spectra 64 k data 
points, line broadening factor = 0.16 Hz, pulse width (PW) = 30 degrees and the relaxation delay d1 = 
1 s. The acquisition temperature was 298 K. 
Topspin software version 3.2 was used for spectra acquisition and processing.  AMIX Bruker Biospin 
multivariate analysis software version 3.0 was used for converting spectra to an ASCII file. The 
numbers of scans chosen was 256 for optimum strength of signal, and locked at zero on the TMS 
peak.  
Data reduction and multivariate statistics methods  
The ¹H-NMR spectra were phase-corrected, baseline-corrected, and zeroed to the TMS peak. The 
spectra were converted to an ASCII file using AMIX software for multivariate analysis.  
AMIX was used to generate a number of integrated regions (buckets) of the data set in the region of 
6.0 to 8.0 ppm. The size of buckets was 0.04 ppm. . The data set was imported to Microsoft EXCEL, 
and the samples and standards were labelled 1 to 37. The Principal Component Analysis (PCA) was 
carried out using SIMCA software version 13.0. 
 
High performance thin layer chromatography (HPTLC)  
Preparations of standard solutions and samples 
The extraction of plant samples was performed according to a method described by the HPTLC 
Association for the identification of dried Ginkgo biloba leaf (www.hptlc-association.org). Standard 
solutions of rutin, chlorogenic acid and quercetin were prepared at a concentration of 0.2 mg/ml in 
methanol. The terpene lactones standard was prepared at concentration of 1 mg/ml. Approximately 
100 mg of solid samples (extracts/products) were weighed individually into 10 ml centrifuge tubes 
and 10 ml of methanol were added. The mixture was sonicated for 10 minutes at room temperature 
and centrifuged for 5 minutes at 5000 rpm. The supernatant solution was transferred into individual 
vials, and then submitted for HPTLC analysis. 
Chromatography 
HPTLC analysis was performed on 20 x 10 cm HPTLC glass plates silica gel 60 F 254 (Merck, Germany). 
Reference solutions and samples were applied onto the plate as bands 8.0 mm wide using a CAMAG 
Automatic TLC Sampler (ATS 4). Bands were applied at a distance of 8.0 mm from the lower edge of 
plate and 20 mm from the left and right edges. The space between bands was 11 mm, and the 
number of tracks per plate was 15. Plates were developed in a CAMAG Automatic Developing 
Chamber (ADC2) to a distance of 70 mm from the lower edge of the plate. Prior to development the 
plates were conditioned to a relative humidity of 33 %.  
Analysis of flavonoids: 3 µL of the samples and standards were applied onto the plate, which was 
developed with the mobile phase ethyl acetate, acetic acid, formic acid, water 100:11:11:27 
(v/v/v/v). For the derivatization procedure, the plate was first heated at 100°C for 3 minutes on a 
CAMAG TLC Plate Heater, then dipped (speed: 3, time: 0) first into NP reagent (1 g of 2-aminoethyl 
diphenylborinate in 200 mL of ethyl acetate) then subsequently into PEG reagent (10 g of 
polyethylene glycol 400 in 200 mL of methylene chloride) using a CAMAG Chromatogram Immersion 
Device. The plates were documented using a CAMAG Visualizer under white light, UV 254 nm, and 
UV 366 nm prior derivatisation and under white light and UV 366 nm after derivatisation with 
visionCATS software. 
Analysis of terpene lactones: Prior to sample application (3 µL of standards and 5 µL of samples), the 
plates were impregnated with 8 g sodium acetate in 200 mL ethanol-water (6:4) by immersion into 
the solution for 2 s, allowed to dry at room temperature for 5 min and then activated for 30 min at 
90°C. Toluene, ethyl acetate, acetone, methanol 20:10:10:1.2 (v/v/v/v) was used as mobile phase. 
After development the plate was sprayed with acetic anhydride, heated at 180°C for 10min and 
documented under UV 366 nm for selective detection of the target compounds.  
 
 
Results and Discussion 
1H-NMR spectroscopy analysis 
On visual inspection, the 1H-NMR raw data suggests that there is considerable variation 
between products (Fig.1). 
 
A closer examination of the NMR spectra shows the typical chemical shift for rutin more clearly and 
moreover many samples appear to contain mainly rutin (Fig.2). 
 
However, the information that can be derived visually from the raw data is limited so SIMCA 
multivariate software offers a suitable tool to analyse the variation in the data. The SIMCA scores 
plot (Fig. 3) confirms that there is wide variation in the chemical composition of the samples. This is 
likely due in part to the samples being formulated into different dosage forms, e.g. capsules and 
tablets, but also different excipients are typically used in the manufacture of different brands of 
product. Consequently, in order to avoid variations in the samples due to excipients, we have 
focused the SIMCA scores plot on the 6 – 8 ppm chemical shift region (where mainly aromatic 
compounds, e.g. flavonoids give signals) and so the scores plot reflects the variation in the 
phytochemistry of the Ginkgo biloba leaf and not any added excipients. 
The scores plot indicates that some samples are similar in chemical composition to the selected 
Ginkgo biloba reference (CRS for peak Identification) and some samples appear similar to the rutin 
standard. This can be seen clearly from the contribution plot (Fig. 4) where, for example, samples 23, 
32 and 33 are very similar in composition to the rutin standard (36) and are weaker in all metabolites 
when compared with the average fingerprint of the other samples, apart from those metabolites 
that correspond in chemical shift to rutin. This observation is further confirmed using the HPTLC data 
where we see that some samples purporting to be Ginkgo biloba only show a band for rutin (Rf 0.38) 
(Fig.6). 
Moreover, the NMR spectroscopy scores plot shows some supplements that are very different in 
chemical composition to that of Ginkgo biloba e.g. sample 7, and again this can be clearly seen on 
the HPTLC analysis. Examination of the NMR spectroscopy raw data for this supplement suggests 
some similarity in structure to 5-hydroxytryptophan (5-HTP). This product was manufactured by the 
same company that our group identified in connection with rhodiola products adulterated with 5-
HTP (Booker et al., 2016). 
 
HPTLC analysis 
All 35 samples were analysed using the HPTLC Association’s methods for identification of dried 
Ginkgo leaf based on flavonoids and terpene lactones. The fingerprints obtained were compared to 
3 samples of Ginkgo leaf and 4 samples of extracts, which are compliant with the respective Ph. Eur. 
monograph (Ph. Eur. 8.8, monographs 1827 and 1828) and USP monographs (Ginkgo and powdered 
Ginkgo extract) (Fig. 5.a and 5.b). One of the extract samples (on Track 5) is a tablet containing a 
special extract (EGb 761).  
Flavonoid fingerprint of the reference material: the fingerprint of the leaf and extract are similar in 
intensity, colour and number of zones except for the reddish zone below the solvent front due to 
chlorophyll, which is only seen in leaf samples. Some of the leaf samples and all extract samples 
show a greenish/brownish zone at the position of quercetin. 
Terpene lactones fingerprint of the reference material: In the fingerprint of the leaf samples (tracks 
2-6) the zones of ginkgolides c, b and bilobalide are not clearly seen due to a matrix interference 
(greenish zone), while in the extracts (tracks 7-9) all zones are well separated. Additionally a red 
zone due to chlorophyll, just below the solvent front, is only seen in leaf samples. The intensity of 
the main four zones seen in the extracts’ fingerprint is equivalent to 6% of the sum of ginkgolides a, 
b, c and bilobalide.  
 
Evaluation of the products: The visual inspection of the HPTLC chromatograms of the 35 products 
reveals a large variation in the intensity and composition of the chemical fingerprint (Fig. 6). Only 
two samples (20 and 33) show a flavonoid fingerprint equivalent to the one of quantified Ginkgo 
reference special extract EGb 761 (track 5, fig. 5.a). However, the fingerprint of sample 33 is 
significantly weaker. The drug extract ratio of this sample was not specified on the label. Therefore 
the weak fingerprint is likely associated to an insufficient amount of material used during sample 
preparation. 
Four samples (14, 23, 30 and 32) show a predominant zone due to rutin and one sample (7) shows 
just a dark blue zone. 26 out of 35 samples show an intense yellow zone at the position of quercetin, 
just below the solvent front (1, 2, 4, 5, 6, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, 21, 22, 24, 25, 27, 28, 
29, 31, 34 and 35). Despite the high amount of quercetin, the fingerprints of these samples, except 
for sample 4, match those of the reference materials shown in Fig. 5.a. Some are just weak. The 
same observation has been made by ( Chandra et al, 2011), who classify the samples with high 
content of quercetin but a profile similar to that of Ginkgo extract in the HPLC fingerprint as category 
of intermediate quality.  
All samples were also  tested for the content of bilobalide, ginkgolides a, b and c (Fig. 7). Four 
samples (7, 23, 30, and 32) showed no zone for terpene trilactones. Those zones were very faint in 
sample 14 and slightly stronger in sample 33 but still weaker than in all other samples. However, on 
their label the samples 7, 14 and 23 claimed to contain 6% of terpene lactones, which should 
produce an intensity equivalent to these of the reference extracts (Fig 5.b, tracks 5-7). Samples 30, 
32 and 33 did not provide any specification about the content of terpene lactones on their labels.  
  
 
A careful evaluation of the samples’ label claims was performed and it was observed that they fell 
into seven general categories, from standardised extracts to no information about the content (see 
table 1). Some samples belong to one or more categories at the same time. Additionally, all samples 
declare to contain Ginkgo (extract or leaf), thus it is expected that their HPTLC fingerprints are 
similar to those obtained for the reference images in Figs 5.a and 5.b. 
Type 1: Of 35 products 18 declare to contain a standardised extract (24% of flavone glycosides and 
6% of terpene lactones). Similar specifications are described in the USP and Ph. Eur. monographs for 
Ginkgo extracts. Therefore, these samples must comply with the amounts of flavone glycoside and 
terpene lactones  stated on the product label (minimum content) and comply with the quantitative 
assays as detailed in the pharmacopoeias. However the assay is not able to show the differences in 
the samples’ composition. Consequently official methods require combining the assay with an 
identification test (e.g. HPTLC identification). In this context, the fingerprints of only 15 samples are 
in compliance with the reference image, even though the yellowish-brown fluorescent zone at the 
position of quercetin in the flavonoid fingerprint is of much higher intensity than that in the 
reference images (Fig. 5a). Three samples from this category (7, 14 and 23) show a very poor 
fingerprint.  
In the identification by TLC/HPTLC neither the intensity of the quercetin is described in the USP and 
Ph. Eur. monographs, nor is it explicitly stated that the yellowish-brown zone describe in the upper 
part of the chromatogram is not quercetin. The intensity of the quercetin zone in the samples of this 
group can therefore not be used as quality criterion. However, from a consumer’s perspective it may 
still be questioned whether a Ginkgo product with high quercetin amount is of equivalent quality to 
a product with low quercetin amount. 
A second group only declares to be standardized to contain 24% of the flavone glycoside (type 2, 
table 1). The fingerprint of all four samples of this group comply with the acceptances criteria for 
identification.  
RF 
Of the products which declare the drug extract ratio (DER) equivalent to 50:1 (type 3), eight provide 
no additional information (type 3.a), 12 declare to be standardized (type 3.b), one declares to 
contain 24% of flavone glycosides (type 3.c) and one declares to contain leaf powder and extract 
(type 3.d). Once the amount of powdered leaf used to produce the extract is declared, it is expected 
that the intensity of the product’s fingerprint is similar to that of the reference material (EGb 761; 
track 7, figs 5.a and b). However none of the samples of type 3 is equivalent. Therefore those 
samples can be considered to contain lower than declared amounts of Ginkgo, based on the 
flavonoids fingerprint.  
Samples 3 and 27 declare to contain Gingko leaf and Ginkgo leaf extract (type 4). The first sample 
shows additional zones on its flavonoid fingerprint, 2 blue fluorescent zones in the upper third of the 
chromatogram, which are neither found in leaf powder nor in the reference extract. Both samples 
show a reddish zone due to chlorophyll in the terpene lactones and flavonoids fingerprints (present 
in the leaf powder). Four samples provided no relevant information about the extract but just the 
amount of extract in the tablet/capsule (type 5). One sample declares to contain an extract 
enhanced with rutin, however its fingerprint has an additional strong zone at the position of 
quercetin (type 6). The samples of type 7 declare to contain only Gingko leaf but their fingerprints 
are different from those of the reference drug (Fig. 5) 
Our study suggests that the main problems are poor concentrations of Ginkgo metabolites, addition 
of marker compounds (rutin) and addition of other compounds e.g. 5-hydroxytryptophan type 
derivatives. 
No sample claims compliance with any pharmacopoeial method but, aside from the 
pharmacopoeias, there are no definitions for Ginkgo leaf and extract. Therefore, it is difficult to 
assign a good or bad quality to label to those samples. Only deviation from the label claim can be 
used for such qualification. On this basis and their HPTLC fingerprints, we may classify the samples to 
have a quality similar to that described in the Pharmacopoeias (samples 20 and 33), bad quality (no 
ginkgo at all) or not in compliance with their label (samples 7, 34, and 28) and a quality different 
from that described in Pharmacopoeias (remaining 30 samples). 
The underlying reason for why there is so much variation in samples is likely to be complex. It may 
be in some cases that the extraction processes are insufficient. . However for the addition of marker 
compounds in order that they may satisfy basic analytical limit tests and the addition of substances 
such as 5-hydroxytryptophan type derivatives, there seems little other recourse than to draw the 
conclusions that these companies are either being sold sub-standard material from third parties or 
are using poor quality and adulterated material intentionally in order to maximise profits. 
The THR scheme was introduced to ensure that herbal medicinal products are of good quality and 
comply with what is claimed on the label. It came under some criticism when it came into force 
claiming that it took away consumers rights to choose. This may be true, but it seems obvious that a 
right to choose a poor quality or fake product is not a right that’s of much value to the general 
consumer of these products. It was further argued that THR products would be too expensive for 
consumers. Our research suggests that THR products are generally mid-price range (comparison of 
our samples against THR products sold on the UK market), with most of the very cheap products 
showing to be of poor quality but in some instances the very expensive products were also 
adulterated or of poor quality. It therefore seems that price is not always a reliable indicator of 
quality. 
Conclusions 
From a regulatory perspective, five samples (7, 14, 23, 28 and 34) are not in compliance with their 
label specification. The other 28 samples can be considered to be in compliance with their label 
claim but their quality is different from that described in pharmacopoeias. This means that these 
samples show different fingerprints with different levels of rutin, quercetin and other additional 
zones. Only two samples (20 and 33) show a fingerprint similar to that described in the Ph.Eur. and 
USP monographs for ginkgo extract. From a consumers perspective it may be legitimate to assume 
that a Ginkgo supplement contains the “same” extract as a registered herbal medicine. However, 
this is not the case. Future investigations into the ratio of different flavonoids e.g. quercetin and 
kaempferol using NMR spectroscopy and HPTLC will provide further evidence as to the kind and 
degree of adulteration of gingko supplements and provide a measure of product quality that helps 
overcoming supplement adulteration. 
In view of the therapeutic claims for Ginkgo, the reported potential side effects / interactions (Abad 
et al. 2010) and the problems identified in this study, it seems appropriate to cover Ginkgo 
preparations with an appropriate medical regulation. Alternatively, a regulatory scheme needs to be 
introduced for food supplements. In addition it is essential to firstly study the value chains of Ginkgo 
biloba products and to clearly identify the crucial points responsible for such poor quality or 
adulteration (Heinrich 2015). In a next step best practice along the value chains needs to be 
established requiring first of all, all producers of final products to gain a detailed understanding of 
the value chains of their products. 
 
These quality problems have important implications for all healthcare practitioners prescribing, 
dispensing or recommending ginkgo-based products. A full verification of the composition and 
quality of the products needs to be ascertained and practitioners will need to implement quality 
assurance measures either on the basis of using fully certified material or implementing such steps 
themselves. In addition patients should be advised accordingly about problems with potentially 
adulterated OTC preparations.  
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 Figure 1, Raw NMR spectra from 35 Ginkgo supplement samples plus rutin reference and Ginkgo 
biloba botanical reference material. 
  
Figure 2, Comparison of rutin reference standard bottom against one of the samples (top) 
  
Figure 3, SCORES plot of 35 Ginkgo supplement samples as well as Rutin and Ginkgo biloba reference 
samples. 
  
ppm 
Figure 4, Contributions plot showing the variation in data between sample 32 (top) which 
shows mainly peaks for pure rutin and the average metabolite content for the rest of the 
samples showing a wide range of ginkgo metabolites. 
  
  
Fig. 5.a, HPTLC chromatograms of the reference tracks under UV 366 nm after derivatisation with 
NP. Track 1: SST (rutin, chlorogenic acid and quercetin with increasing RF values); Track 2: Ginkgo 
leaf sample (S1310); Track 3: Ginkgo leaf sample (S11311); Track 4: Ginkgo leaf sample (S15564); 
Track 5: tablet with quantified Ginkgo leaf extract EGb 761; Track 6: Ginkgo leaf extract (S15571); 
Track 7: Ginkgo leaf extract (S1312); Track 8: Ginkgo leaf extract (S10925); 
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RF 
  
  
 
 
Fig. 5.b, HPTLC chromatograms of the reference tracks under UV 366 nm after derivatisation with 
acetic anhydride. Track 1: SST (Ginkgolides c, j, b and a and bilobalide with increasing RF values); 
Track 2: Ginkgo leaf sample (S1310); Track 3: Ginkgo leaf sample (S11312); Track 4: Ginkgo leaf 
sample (S15564); Track 5: tablet with quantified Ginkgo leaf extract EGb 761; Track 6: Ginkgo leaf 
extract (S15571); Track 7: Ginkgo leaf extract (S10925); 
    1             2              3             4               5             6              
7            
RF 
  
Figure 6, HPTLC chromatograms of products 1-35 under UV 366 nm after derivatisation of the 35 
Ginkgo products evaluated with flavonoids method. SST: rutin, chlorogenic acid and quercetin with 
increasing RF values 
RF 
  
Figure 7, HPTLC chromatograms of products 1-35 under UV 366 nm after derivatization of the 35 
Ginkgo products evaluated with terpene trilactones method. SST: Ginkgolides c, j, b, a, and bilobalide 
with increasing RF values.  
RF 
Table 1: classification of the products according to their label claim  
Type Label claim total Sample(s) number 
1 Extracts standardised to contain 24% of flavone 
glycoside and 6% of terpene lactones 18 
1, 2, 4, 6, 7, 9, 11, 12, 14, 
17, 21, 22, 23, 25, 24, 29, 
31, 35 
2 Extracts standardised to contain 24% of flavone 
glycoside (solely)  
4 
5, 8, 20, 27 
3.a  Provide the drug extract ratio (50:1) but no 
additional information  
19 
10, 13, 15, 16, 18, 19, 26, 30 
3.b provide the drug extract ratio (50:1) and declare to 
contain 24% of flavone glycoside and 6% of terpene 
lactones 
1, 7, 11, 14, 17, 21, 22, 29, 
31 
3.c Provide the drug extract ratio (50:1) and declare to 
contain 24% of flavone glycoside 
5 
3.d Provide the drug extract ratio (50:1) and to contain 
both leaf powder and extract 
3 
4 Declare to contain Ginkgo leaf powder and extract  2 3 (?), 27 
5 No specification about the extract 4 28, 32, 33, 34 
6 Extract enhanced with Rutin 1 29 
7 Only leaf powder (no extract) 2 34, 28 
 
 
